卡斯爾曼氏病治療的全球市場 - 2022-2029
市場調查報告書
商品編碼
1004982

卡斯爾曼氏病治療的全球市場 - 2022-2029

Global Castleman Disease Treatment Market - 2022-2029

出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 約2個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場動態

研究機構進行的卡斯爾曼病治療臨床試驗預計將推動市場增長。

卡斯爾曼氏病協作網絡 (CDCN) 與賓夕法尼亞大學和阿肯色大學醫學院合作,與研究藥物西羅莫司合作,用於治療對抗 IL 無反應的特發性多中心 卡斯爾曼氏病 (iMCD) 成人-6 療法。正在進行測試。西妥昔單抗 (Silvant) 和托珠單抗是兩種抗 IL-6 藥物 (Actemra)。此外,中國北京的北京協和醫院正在招募參與者進行一項臨床試驗,以測試硼替佐米、環磷□胺和地塞米松(BCD 方案)的有效性和安全性。因此,上述聲明預計將在預測期內推動市場。

約束

由於該疾病的低流行率和對該疾病的了解不足,人們的意識低下。在預測期內,預計幾家公司的治療成本上升和專利到期將阻礙市場。

COVID-19 影響分析

COVID-19 大流行對醫療保健系統和市場產生了適度影響。 siltoximab 和 tocilizumab 等抗 IL6 藥物也用於治療一些危重患者的 COVID-19 誘導的細胞因子風暴。此外,siltoximab 和 tocilizumab 等抗 IL6 藥物現已被確定為一些特發性多中心 卡斯爾曼氏病患者的有效治療方法。這些藥物可以短期緩解症狀,但也很安全,可以長期控制那些有反應的人。在 COVID-19 大流行期間,CDCN 了解 siltoximab 和 tocilizumab 的短缺情況。 CDCN 擔心這些重要藥物對 卡斯爾曼氏病患者的可用性。 CDCN獲悉,siltoximab和tocilizumab的生產商已承諾為卡斯爾曼氏病患者提供藥物。因此,許多公司轉移到其他地區以確保產品可用性並保護其供應鏈。這樣一來,市場受到了影響,但隨著經濟活動的恢復,預計將獲得動力。

全球城堡疾病治療市場報告提供大約 45 多個市場數據表、40 多個數字和 180 頁內容。

內容

第一章研究方法與範圍

  • 調查方法
  • 調查目的和範圍

第 2 章市場定義和概述

第 3 章執行摘要

  • 按類型劃分的市場細分
  • 按診斷劃分的市場細分
  • 按處理方法劃分的市場細分
  • 最終用戶的市場細分
  • 市場細分:按分銷渠道
  • 按地區劃分的市場細分

第 4 章市場動態

  • 市場影響因子
    • 驅動程序
      • 研究機構治療卡斯爾曼病的臨床試驗預計將推動市場增長。
    • 限制
      • 預計飆升的處理成本將阻礙市場增長。
    • 機會
    • 影響分析

第五章行業分析

  • 供應鏈分析
  • 定價分析
  • 未滿足的需求分析

第 6 章 COVID-19 分析

  • COVID-19 的市場分析
    • COVID-19 之前的市場情景
    • COVID-19 的當前市場情景
    • COVID-19 後或未來情景
  • COVID-19 期間的價格動態
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措
  • 總結

第 7 章按類型

  • 單核卡斯爾曼氏病
  • 多中心卡斯爾曼氏病

第8章診斷

  • 驗血/驗尿
  • 圖像檢查
    • X 射線檢測
    • CT 掃描
    • 其他
  • 淋巴結活檢
  • 其他

第 9 章治療

  • 免疫療法
    • 西妥昔單抗(思萬特)
    • 利妥昔單抗(利妥昔單抗)
    • 其他
  • 化療
  • 皮質類固醇
    • 潑尼松
    • 托珠單抗
    • 來那度胺
    • 糖皮質激素
    • 其他
  • 抗病毒劑
    • 更昔洛韋
    • 其他

第 10 章,最終用戶

  • 醫院
  • 診所
  • 門診手術中心
  • 診斷中心
  • 其他

第 11 章分銷渠道

  • 醫院藥房
  • 零售藥房
  • 在線藥店
  • 其他

第 12 章按地區劃分

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第 13 章競爭格局

  • 主要發展和戰略
  • 公司份額分析
  • 產品基準
  • 值得關注的重點公司列表

第 14 章公司簡介

  • EUSA 製藥
    • 公司概況
    • 產品組合和描述
    • 主要亮點
    • 財務摘要
  • Johnson & Johnson Services, Inc.
  • Genentech USA, Inc.
  • F. Hoffmann-La Roche Ltd
  • Amgen Inc.
  • Bristol-Myers Squibb Company
  • Par Pharmaceutical
  • Exela Pharma Sciences

第15章 卡斯爾曼氏病治療的全球市場-DataM

簡介目錄
Product Code: DMPH3381

Market Overview

The Global Castleman Disease Treatment Market is expected to grow at a high CAGR during the forecasting period (2022-2029).

Castleman disease is a rare disorder in which cells in the lymph nodes grow out of control. The most prevalent form of the disorder (unicentric Castleman disease) involves a single lymph node in the chest or belly. Depending on the patient's type of Castleman disease, treatment and prognosis will differ. Surgery is frequently successful in treating the type that involves only one lymph node.

Market Dynamics

Clinical trials conducted by the research institutes for the treatment of Castleman Disease are expected to drive market growth.

The Castleman Disease Collaborative Network (CDCN) has teamed up with the University of Pennsylvania and the University of Arkansas for Medical Sciences to conduct a study of sirolimus, an investigational medicine, for adults with idiopathic multicentric Castleman disease (iMCD) who have failed to respond to anti-IL-6 therapies. Siltuximab (Sylvant) and tocilizumab are two anti-IL-6 drugs (Actemra). Moreover, The Peking Union Medical College Hospital in Beijing, China, sought participants for a clinical trial examining the efficacy and safety of the drugs bortezomib, cyclophosphamide, and dexamethasone (BCD regimen). Thus, the market is expected to drive in the forecast period from the above statements.

Restraint:

Due to the disease's low prevalence rate and a lack of knowledge about it, there is a lack of awareness. The Patent expiry of several companies associated with the high cost of treatment are factors the market is expected to hamper in the forecast period.

COVID-19 Impact Analysis

The COVID-19 pandemic has moderately impacted healthcare systems and the market. Anti-IL6 drugs like siltuximab and tocilizumab are also being used to treat COVID-19-induced cytokine storms in some critically ill patients. Moreover, Anti-IL6 medicines like siltuximab and tocilizumab are now well-established as viable treatments for some individuals with idiopathic multicentric Castleman disease. These drugs alleviate symptoms in the short term, but they are also safe and provide long-term disease control in responders. During the COVID-19 pandemic, the CDCN understands a supply shortfall of siltuximab and tocilizumab. The CDCN is concerned about the availability of these important medications for Castleman Disease patients. The CDCN learned that the producers of siltuximab and tocilizumab are committed to providing the drugs to individuals with Castleman Disease. Therefore, many companies will vary to other geographic regions to ensure that products remain available and protect their supply chain. Thus, from the above statements, the market got affected, and it is expected to gain traction quickly with the resumption of the economic activities.

Segment Analysis

Immunotherapy segment is expected to hold the largest market share in castleman disease treatment market

The immunotherapy segment is expected to dominate in 2021. The segment is benefitted because drugs like siltuximab (Sylvant) and rituximab (Rituxan) can inhibit the function of a protein that is overproduced in persons with multicentric Castleman disease. Moreover, medicines and other therapies to control cell overgrowth are commonly used to treat multicentric Castleman disease. Treatment options vary depending on the severity of your illness and whether the patient has HIV, HHV-8, or both. Therefore, these agents do not only control symptoms short-term but continued administration to responders is safe and provides durable disease control. Thus, the market segment is expected to hold the largest market share in the forecast period from the above statements.

Geographical Analysis

North America region holds the largest market share in the global castleman disease treatment market

In 2021, North America accounted for the highest revenue share. The increasing prevalence of idiopathic multicentric Castleman disease (iMCD), well-established infrastructure, companies focusing on research & development and performing clinical trials and the presence of major players as well as government measures that aid medicine development for orphan diseases are some of the factors the market is expected to boost in the forecast period. For instance, it is estimated that 6500 to 7700 new cases are diagnosed each year in the United States; approximately 1000 of those are HHV-8-associated multicentric Castleman disease (HHV-8-associated MCD), and 1000 are HHV-8-negative MCD. Moreover, The Castleman Disease Collaborative Network (CDCN) has teamed up with the University of Pennsylvania and the University of Arkansas for Medical Sciences to conduct a study of sirolimus, an investigational medicine, for adults with idiopathic multicentric Castleman disease (iMCD) who have failed to respond to anti-IL-6 therapies. Siltuximab (Sylvant) and tocilizumab are two anti-IL-6 drugs (Actemra). Thus, the North American region is expected to hold the largest market share in the forecast period from the above statements.

Competitive Landscape

Major key players in the castleman disease treatment market are EUSA Pharma, Johnson & Johnson Services, Inc., Genentech USA, Inc., F. Hoffmann-La Roche Ltd, Amgen Inc., Bristol-Myers Squibb Company, Par Pharmaceutical, Exela Pharma Sciences.

EUSA Pharma:

Overview:

EUSA Pharma was founded in March 2006. It is a newly-established, profitable specialty pharmaceutical company with global reach from its UK headquarters and commercial operations across Europe and the USA. It is focused on oncology and rare disease, continuously striving to confront gaps in patient care. EUSA Pharma also has a wide distribution network of commercial partners in Europe, the Middle East, Asia and Latin America. It makes products available in approximately 40 countries worldwide through this broad international platform.

­Product Portfolio:

SYLVANT (siltuximab): It is the first and only FDA/EMA approved therapy for idiopathic Multicentric Castleman Disease (iMCD) and is recommended as the preferred first line therapy by clinical guidelines.

Why Purchase the Report?

Visualize the composition of the castleman disease treatment market segmentation by type, diagnosis, treatment, end user, distribution channel, and region highlighting the key commercial assets and players.

Identify commercial opportunities in castleman disease treatment market by analyzing trends and co-development deals.

Excel data sheet with thousands of data points of castleman disease treatment market- level 4/5 segmentation.

PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.

Product mapping in excel for the key product of all major market players

The global castleman disease treatment market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.

Target Audience

Service Providers/ Buyers

Industry Investors/Investment Bankers

Education & Research Institutes

Research Professionals

Emerging Companies

Manufacturers

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

  • 3.1. Market Snippet by Type
  • 3.2. Market Snippet by Diagnosis
  • 3.3. Market Snippet by Treatment
  • 3.4. Market Snippet by End user
  • 3.5. Market Snippet by Distribution channel
  • 3.6. Market Snippet by Region

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Clinical trials conducted by the research institutes for the treatment of Castleman Disease are expected to drive market growth.
    • 4.1.2. Restraints:
      • 4.1.2.1. High cost of treatment is expected to hamper the market growth.
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Supply Chain Analysis
  • 5.2. Pricing Analysis
  • 5.3. Unmet Needs

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 7.1.2. Market Attractiveness Index, By Type Segment
  • 7.2. Unicentric Castleman disease*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Multicentric Castleman disease

8. By Diagnosis

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 8.1.2. Market Attractiveness Index, By Diagnosis Segment
  • 8.2. Blood and urine tests*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Imaging tests
    • 8.3.1. X-rays
    • 8.3.2. CT Scans
    • 8.3.3. Others
  • 8.4. Lymph node biopsy
  • 8.5. Others

9. By Treatment

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 9.1.2. Market Attractiveness Index, By Treatment Segment
  • 9.2. Immunotherapy*
    • 9.2.1. Siltuximab (Sylvant)
    • 9.2.2. Rituximab (Rituxan)
    • 9.2.3. Others
    • 9.2.4. Introduction
    • 9.2.5. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Chemotherapy
  • 9.4. Corticosteroids
    • 9.4.1. Prednisone
    • 9.4.2. Tocilizumab
    • 9.4.3. Lenalidomide
    • 9.4.4. Glucocorticoids
    • 9.4.5. Others
  • 9.5. Antiviral drugs
    • 9.5.1. Ganciclovir
    • 9.5.2. Others

10. By End user

    • 10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 10.1.2. Market Attractiveness Index, By End user Segment
  • 10.2. Hospitals*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 10.3. Clinics
  • 10.4. Ambulatory Surgical Centers
  • 10.5. Diagnostic Centers
  • 10.6. Others

11. By Distribution Channel

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.1.2. Market Attractiveness Index, By Distribution Channel Segment
  • 11.2. Hospital Pharmacies*
    • 11.2.1. Introduction
    • 11.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 11.3. Retail Pharmacies
  • 11.4. Online Pharmacies
  • 11.5. Others

12. By Region

  • 12.1. Introduction
    • 12.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 12.1.2. Market Attractiveness Index, By Region
  • 12.2. North America
    • 12.2.1. Introduction
    • 12.2.2. Key Region-Specific Dynamics
    • 12.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 12.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 12.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 12.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 12.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.2.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 12.2.8.1. U.S.
      • 12.2.8.2. Canada
      • 12.2.8.3. Mexico
  • 12.3. Europe
    • 12.3.1. Introduction
    • 12.3.2. Key Region-Specific Dynamics
    • 12.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 12.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 12.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 12.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 12.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.3.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 12.3.8.1. Germany
      • 12.3.8.2. U.K.
      • 12.3.8.3. France
      • 12.3.8.4. Italy
      • 12.3.8.5. Spain
      • 12.3.8.6. Rest of Europe
  • 12.4. South America
    • 12.4.1. Introduction
    • 12.4.2. Key Region-Specific Dynamics
    • 12.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 12.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 12.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 12.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 12.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.4.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 12.4.8.1. Brazil
      • 12.4.8.2. Argentina
      • 12.4.8.3. Rest of South America
  • 12.5. Asia Pacific
    • 12.5.1. Introduction
    • 12.5.2. Key Region-Specific Dynamics
    • 12.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 12.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 12.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 12.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 12.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.5.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 12.5.8.1. China
      • 12.5.8.2. India
      • 12.5.8.3. Japan
      • 12.5.8.4. Australia
      • 12.5.8.5. Rest of Asia Pacific
  • 12.6. Middle East and Africa
    • 12.6.1. Introduction
    • 12.6.2. Key Region-Specific Dynamics
    • 12.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 12.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 12.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 12.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 12.6.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

13. Competitive Landscape

  • 13.1. Key Developments and Strategies
  • 13.2. Company Share Analysis
  • 13.3. Product Benchmarking
  • 13.4. List of Key Companies to Watch

14. Company Profiles

  • 14.1. EUSA Pharma*
    • 14.1.1. Company Overview
    • 14.1.2. Product Portfolio and Description
    • 14.1.3. Key Highlights
    • 14.1.4. Financial Overview
  • 14.2. Johnson & Johnson Services, Inc.
  • 14.3. Genentech USA, Inc.
  • 14.4. F. Hoffmann-La Roche Ltd
  • 14.5. Amgen Inc.
  • 14.6. Bristol-Myers Squibb Company
  • 14.7. Par Pharmaceutical
  • 14.8. Exela Pharma Sciences

LIST NOT EXHAUSTIVE

15. Global Castleman Disease Treatment Market - DataM

  • 15.1. Appendix
  • 15.2. About Us and Applications
  • 15.3. Contact Us